Diphosphonate bone scanning agents — Current concepts
✍ Scribed by Ignac Fogelman
- Book ID
- 104687028
- Publisher
- Springer
- Year
- 1982
- Tongue
- English
- Weight
- 464 KB
- Volume
- 7
- Category
- Article
- ISSN
- 0340-6997
No coin nor oath required. For personal study only.
✦ Synopsis
The bone scan is generally recognized to be an extremely powerful investigational tool in the evaluation of patients with skeletal disease. Currently 99mTc-methylene diphosphonate is the most widely used bone scanning agent, but recently several new diphosphonate compounds have been introduced which appear to have relatively higher skeletal affinity, leading to greater absolute uptake of tracer by bone. While the resulting improved contrast between bone and background soft-tissue may provide more pleasing scan images, it is not clear that increased bone uptake of tracer is equally desirable for identification of disease. Nevertheless, to date, no significant difference in lesion detection has been found in any comparative study of diphosphonate compounds. In this review the clinical studies evaluating diphosphonate bone scanning agents are summarized and the properties required of an ideal bone scanning agent in both benign and malignant disease discussed.
📜 SIMILAR VOLUMES
A positive 99mTc-methylene diphosphonate bone scan was obtained in a case of pelvic osteomyelitis in a 15-year-old girl. An 111In-labelled leucocyte scan confirmed the presence of pus, gave a more accurate anatomical location than was obtained by the bone scan, and enabled the most suitable surgical
99mTc-methylene diphosphonate (MDP) bone scintigraphy demonstrated localization in an intracranial metastasis of osteogenic sarcoma. This unusual case suggests that bone scintigraphy may have diagnostic value in the early diagnosis of metastatic ossifying lesions.